Abstract
ABSTRACT Introduction Patients with schizophrenia often relapse as a result of medication nonadherence. Methods Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
